In Vitro Comparison of Output and Particle Size Distribution of Budesonide from Metered-Dose Inhaler with Three Spacer Devices during Pediatric Tidal Breathing.

Wolfgang Kamin, Hilke Ehlich
{"title":"In Vitro Comparison of Output and Particle Size Distribution of Budesonide from Metered-Dose Inhaler with Three Spacer Devices during Pediatric Tidal Breathing.","authors":"Wolfgang Kamin,&nbsp;Hilke Ehlich","doi":"10.2165/00151829-200605060-00013","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>The aim of this in vitro study was to determine the delivered dose of budesonide 200mug via a chlorofluorocarbon-free pressurized metered dose inhaler (pMDI) when administered through different spacers in tidal breathing patterns of young children.</p><p><strong>Methods: </strong>Tidal breathing was simulated for toddlers and children. Spacers tested were Babyhaler((R)), AeroChamber((R)) Plus small and medium; the pMDI was Budiair((R)) 200microg. Output was measured after one actuation and five inhalations in primed and unprimed spacers. Cumulated output was evaluated after each of five simulated inhalations. Aerosol characteristics - i.e. particle size distribution of the output - were determined in primed spacers with a cascade impactor using high-performance liquid chromatography and UV detection.</p><p><strong>Results: </strong>Total output from primed spacers after five inhalations was determined between 37.9microg and 40.9microg with little differences between spacers and breathing patterns. About 58-79% of this total output was inhaled with the first breath from the AeroChamber((R)) Plus and about 26% from the Babyhaler((R)). The fine particles <5mum ranged between 87% and 92% of the delivered dose for all three spacers.</p><p><strong>Discussion and conclusion: </strong>The nominal dose (200microg) of the Budiair((R)) 200microg inhaler is reduced to 40microg delivered dose or less by using Babyhaler((R)) and AeroChamber((R)) Plus spacers taking five breaths. With a single breath the delivered dose can be reduced further to a minimum of 10microg using the Babyhaler((R)). Clinical studies are warranted in the future for decisions on 'clinical efficacy', safety, and exact dose adjustment.</p>","PeriodicalId":87162,"journal":{"name":"Treatments in respiratory medicine","volume":"5 6","pages":"503-8"},"PeriodicalIF":0.0000,"publicationDate":"2006-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2165/00151829-200605060-00013","citationCount":"6","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Treatments in respiratory medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2165/00151829-200605060-00013","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 6

Abstract

Objectives: The aim of this in vitro study was to determine the delivered dose of budesonide 200mug via a chlorofluorocarbon-free pressurized metered dose inhaler (pMDI) when administered through different spacers in tidal breathing patterns of young children.

Methods: Tidal breathing was simulated for toddlers and children. Spacers tested were Babyhaler((R)), AeroChamber((R)) Plus small and medium; the pMDI was Budiair((R)) 200microg. Output was measured after one actuation and five inhalations in primed and unprimed spacers. Cumulated output was evaluated after each of five simulated inhalations. Aerosol characteristics - i.e. particle size distribution of the output - were determined in primed spacers with a cascade impactor using high-performance liquid chromatography and UV detection.

Results: Total output from primed spacers after five inhalations was determined between 37.9microg and 40.9microg with little differences between spacers and breathing patterns. About 58-79% of this total output was inhaled with the first breath from the AeroChamber((R)) Plus and about 26% from the Babyhaler((R)). The fine particles <5mum ranged between 87% and 92% of the delivered dose for all three spacers.

Discussion and conclusion: The nominal dose (200microg) of the Budiair((R)) 200microg inhaler is reduced to 40microg delivered dose or less by using Babyhaler((R)) and AeroChamber((R)) Plus spacers taking five breaths. With a single breath the delivered dose can be reduced further to a minimum of 10microg using the Babyhaler((R)). Clinical studies are warranted in the future for decisions on 'clinical efficacy', safety, and exact dose adjustment.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
三种间隔装置布地奈德计量吸入器在儿童潮汐呼吸过程中输出量和粒径分布的比较。
目的:本体外研究的目的是确定布地奈德200mug在幼儿潮汐式呼吸方式中通过不同间隔剂经不含氟氯化碳的加压计量吸入器(pMDI)给药时的给药剂量。方法:对幼儿和儿童进行潮汐呼吸模拟。测试的垫片有Babyhaler((R)), AeroChamber((R)) Plus小型和中型;pMDI为Budiair((R)) 200mg。在一次启动和五次吸入带底料和未带底料的间隔剂后测量输出。在五次模拟吸入后评估累计输出量。气溶胶特性——即输出的粒径分布——是用高效液相色谱法和紫外检测仪用级联冲击器在带底漆的间隔器中测定的。结果:5次吸入后,预喷间隔剂的总输出量在37.9 ~ 40.9 μ g之间,间隔剂与呼吸方式差异不大。其中约58-79%的总输出是在第一次呼吸时从AeroChamber((R)) Plus吸入,约26%从Babyhaler((R))吸入。讨论和结论:使用Babyhaler((R))和AeroChamber((R)加上间隔器进行五次呼吸,Budiair((R)) 200微克吸入器的额定剂量(200微克)减少到40微克或更少。使用Babyhaler((右)),单次呼吸的剂量可以进一步降低到最低10微克。今后需要进行临床研究,以确定“临床疗效”、安全性和准确的剂量调整。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Idiopathic Pulmonary Fibrosis Nosocomial pneumonia : rationalizing the approach to empirical therapy. Managing asthma in expectant mothers. New strategies for the treatment of pulmonary hypertension in sickle cell disease : the rationale for arginine therapy. Antioxidant strategies in respiratory medicine.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1